Skip Ribbon Commands
Skip to main content
CIBMTR

COVID-19 Updates

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   /   COVID-19 Updates
  • Print
  • Share

 COVID-19 Updates

Reported Data
Data Collection
Published Study Results
Ongoing Studies
Communications
Additional Resources


COVID-19 Reported Data

As of 6/2/20

Number of COVID-19 Infections: 137

Number of Centers Reporting: 58 (50 US, 8 non-US)

 


SEE DATA BREAKDOWNS BY:

  • Patient sex
  • Type of cellular therapy
  • Age at infection
  • US region
  • Time from infusion

Data Collection

Quick Links:

The CIBMTR continues to collect data and reimburse centers. FormsNet3 and CIBMTR Center Support are fully operational.

New Form: Respiratory Virus Post-Infusion Data Form (2149)

New COVID-19 Diagnosis on Data Collection Forms

  • COVID-19 diagnosis can now be reported on the F2100 and F4100. More information: 3/26/20
  • F2400, F4000, F2450, and F2900 now include questions related to COVID-19 infections. More information: 4/10/20, 5/11/20

Continue to Consent Patients to the Research Database

  • Consent can be obtained by the clinician consenting the patient to HCT or other cellular therapy.
  • No evaluations or appointments are required that are not standard of care.
  • There is no additional risk to patients, clinicians, or study staff.
  • Position statement from the CIBMTR and ASTCT, urging continued consent and enrollment of patients in the CIBMTR's Database Protocol.

Prioritize Data Collection for:

  • Respiratory Virus Post-Infusion Data Form (2149)
  • Consecutive Transplant Audit
  • Recipients on studies, especially BMT CTN
  • More information: 3/20/20, 4/10/20, 5/1/20

Suspension of CPI and One Year Forms Due Requirement for Reimbursement, Evaluation of Data Audits

  • Continuous process improvement (CPI) requirements are suspended until further notice. More information: 3/16/20, 5/1/20
  • Requirement that forms be submitted within one year of their due date in order to be reimbursed is suspended for forms due 3/1/20 or later. More information: 4/1/20
  • On-site CIBMTR data audits are evaluated 8 weeks prior to the scheduled date. If the on-site audit cannot be conducted, audits may be conducted remotely or rescheduled for a later date. More information: 3/20/20, 5/1/20

COVID-19 Published Study Results

Frigault MJ, Nikiforow S, Mansour M, et al. Tocilizumab not associated with increased infection risk after CAR T - Implications for COVID-19? Blood. 2020 May 26. doi.org/10.1182/blood.20200062. [Epub ahead of print]

  • Conclusion: Data suggest early and limited intervention with tocilizumab does not increase the infectious risk in a significantly immunocompromised group of patients.

Eapen M, Zhang MJ, Tang XY, et al. Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia. Biology of Blood and Marrow Transplantation. 2020 May 8. doi:10.1016/j.bbmt.2020.04.027. [Epub ahead of print]

Hamadani M, Zhang M-J, Tang X-Y, et al. Graft cryopreservation does not impact overall survival after allogeneic HCT using post-transplant cyclophosphamide for GVHD prophylaxis. Biology of Blood and Marrow Transplantation. 2020 Apr 10.
doi:10.1016/j.bbmt.2020.04.001. [Epub ahead of print]

  • Conclusion: Graft cryopreservation does not significantly delay hematopoietic recovery, increase acute GVHD risk or non-relapse mortality, or decrease overall survival after allogeneic HCT using posttransplant cyclophosphamide.
  • Plain language summary: Freezing cells for blood and marrow transplant saves lives


Ongoing Studies

Working Committee Studies Continue

  • If you are a study PI, let your statistician know if you are unable to maintain your previous study timeline.
  • Studies requiring supplemental data collection will likely be delayed.
  • More information: 3/27/20

RCI BMT and BMT CTN Trials Affected

  • Accrual is temporarily suspended for some trials, and accrual is restricted for others.
  • On-site monitoring is suspended.
  • More information: BMT CTN SharePoint website (password required)

Communications

COVID-19
​May 11, 2020Respiratory Virus Post-Infusion Form (2149) Released in FormsNet3; Additional Form Modifications (PDF)
​May 1, 2020

​Continuous Process Improvement (CPI), Consecutive Transplant Audit (CTA), and Clinical Data Validation (Audit) (PDF)

​April 21, 2020

​Updates to the Fillable PDF Respiratory Virus Post-Infusion Form (2149) (PDF)

​April 15, 2020

Email to Medical Directors: 
Continuing to Register Patients with CIBMTR (PDF)

Position Statement: Reporting to the CIBMTR during the COVID-19 Pandemic (PDF)

​April 10, 2020

​Form 2149 FAQ, FormsNet Spring Released Delayed & Reporting Priorities (PDF)

​April 1, 2020

Reimbursement for Forms Submitted One Year After Due Date & Respiratory Virus Post-Infusion Form (2149) (PDF)

​March 27, 2020

Working Committees and the CIBMTR

March 26, 2020

​Collecting Data on the Impact of the COVID-19 Pandemic on our Transplant and Cell Therapy Recipients (PDF)

​March 24, 2020

​COVID-19 Impact to CIBMTR International Centers (PDF) 

​March 20, 2020

​COVID-19 Impact to CIBMTR Network Centers in the US (PDF)

​March 16, 2020

COVID-19 and CPI Standards (PDF)


Additional Resources

ASTCT's COVID-19 Resource Community

Be The Match's COVID-19 FAQs




Last Updated: 6/2/2020 9:32 AM
CIBMTR